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MaOBJECTIVES The purpose of this prospective study was to examine the relationship between plasma lipoprotein–
associated phospholipase A2 (Lp-PLA2) activity and the progression rate of aortic stenosis (AS).
BACKGROUND We recently reported that Lp-PLA2 is highly expressed in stenotic aortic valves where it may contribute
to the mineralization of valvular interstitial cells.
METHODS Patients with AS were prospectively recruited in the PROGRESSA (Metabolic Determinants of the Progression
of Aortic Stenosis) study. AS progression rate was assessed by annualized increase in peak aortic jet velocity (Vpeak), mean
gradient (MG), and aortic valve area index (AVAi). Circulating Lp-PLA2 activity was measured and dichotomized based on
the median value.
RESULTS Of 183 patients included in this subanalysis of the PROGRESSA study, 70% were men and the mean age
was 66  13 years. Over the 2.5 1.4 years of follow up, the AS progression rate tended to be higher in patients with high
versus low Lp-PLA2 activity (annualized Vpeak ¼ 0.17  0.23 m/s vs. 0.12  0.18 m/s; p ¼ 0.14). There was a signiﬁcant
interaction (p < 0.05) between baseline AS severity and Lp-PLA2 activity with respect to impact on AS progression rate.
In patients with mild AS (i.e., Vpeak <3 m/s; n ¼ 123), increased Lp-PLA2 activity was associated with a signiﬁcantly faster
AS progression rate (Vpeak 0.16  0.18 m/s vs. 0.09  0.14 m/s; p ¼ 0.01) but not in patients with moderate or severe
AS (p ¼ 0.99). After adjustment for other risk factors, increased Lp-PLA2 activity remained independently associated
with faster AS progression rate (p ¼ 0.005) in the former subset.
CONCLUSIONS There was no signiﬁcant association between plasma Lp-PLA2 activity or mass and stenosis progression
in the whole cohort. However, increased Lp-PLA2 activity was associated with a faster stenosis progression rate in the
subset of patients with mild AS. These ﬁndings provide an impetus for the elaboration of a randomized trial targeting
Lp-PLA2 activity in patients with early stages of calciﬁc aortic valve disease. (J Am Coll Cardiol Img 2015;8:26–33)
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AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
AV = aortic valve
AVAi = aortic valve area index
BSA = body surface area
HDL = high-density lipoprotein
LDL = low-density lipoprotein
Lp-PLA2 = lipoprotein-
associated phospholipase A2
LPC = lysophosphatidylcholine
LVEF = left ventricular
ejection fraction
MG = mean transvalvular
pressure gradient
Vpeak = peak aortic jet velocity
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27C alciﬁc aortic stenosis (AS) is a chronic andmultifactorial disorder characterized by anabnormal mineralization of aortic valve (AV)
cusps (1). The pathological processes that lead to
ectopic mineralization of the valvular tissue may
involve lipid-derived factors (1). Studies conducted
with human AS valve specimens demonstrated that
oxidized low-density lipoprotein (LDL) accumulates
in areas of inﬂammation and mineralization (2,3). Cir-
culating levels of oxidized LDL are positively associ-
ated with several indexes of aortic valve remodeling,
suggesting that oxidized-derived lipids may play a sig-
niﬁcant role in the development of AS (4).
Lipoprotein-associated phospholipase A2 (Lp-
PLA2) uses oxidized LDL as substrate and produces
free fatty acids and lysophosphatidylcholine (LPC), a
powerful proinﬂammatory and procalcifying factor
(5). We recently reported that Lp-PLA2 is highly
expressed in stenotic AVs and that LPC induces
mineralization of valvular interstitial cells in vitro (6).
In another recent cross-sectional study, plasma levels
of Lp-PLA2 was increased in patients with AS (7).SEE PAGE 34These ﬁndings support the hypothesis that
Lp-PLA2 may play a role in AV mineralization. The
objective of this prospective study was thus to
examine the relationship between circulating Lp-
PLA2 activity and the progression rate of AS.
METHODS
PATIENT POPULATION. Patients with AS recruited in
the PROGRESSA (Metabolic Determinants of the Pro-
gression of Aortic Stenosis) study underwent Doppler
echocardiography annually. Inclusion criteria were 21
years of age and older and peak aortic jet velocity
(Vpeak) >2.0 m/s. Patients were excluded if they had
symptomatic AS, moderate to severe aortic regurgi-
tation or mitral valve disease (mitral stenosis or
regurgitation), and left ventricular ejection fraction
(LVEF) <50%, and if they were pregnant or lactating.
The study was approved by the Ethics Committee of
the Quebec Heart and Lung Institute, and patients
signed a written informed consent at the time of in-
clusion in the study. Among the 216 patients recruited
until March 31, 2014, 183 patients with at least 1 year
of follow-up were included in the present subanalysis
of the PROGRESSA study.
CLINICAL DATA. Clinical data included age, sex,
height, weight, body surface area (BSA), body mass
index, systolic and diastolic blood pressures, docu-
mented diagnoses of hypertension (patients taking
antihypertensive medications or having known but
untreated hypertension [blood pressure $140/90mm Hg]), diabetes (patients taking antidia-
betic medication or, in the absence of such
medication, having a fasting glucose $7
mmol/l), dyslipidemia (patients taking
cholesterol-lowering medication or, in the
absence of such medication, having a total
plasma cholesterol level >6.2 mmol/l), and
coronary artery disease (history of myocar-
dial infarction or coronary artery stenosis on
coronary angiography).
LABORATORY DATA. Fasting plasma sam-
ples were collected to measure levels of
glucose and creatinine as well as a complete
lipid proﬁle, which included total cholesterol,
LDL cholesterol, high-density lipoprotein
(HDL) cholesterol, and triglycerides using
automated techniques standardized with the
Canadian reference laboratory.
After centrifugation, plasma samples were stored
at 80C for future measurements of Lp-PLA2 activity
and mass. Brieﬂy, circulating Lp-PLA2 activity was
measured by a commercial colorimetric activity
method (Alanine Transaminase Colorimetric Activity
Assay Kit, Cayman Chemical, Ann Arbor, Michigan).
We also measured the Lp-PLA2 mass using a com-
mercial ELISA kit (R&D Systems, Minneapolis, Min-
nesota). Results were expressed as nanomole per
minute per milliliter for Lp-PLA2 activity and nano-
gram per milliliter for Lp-PLA2 mass.
DOPPLER ECHOCARDIOGRAPHIC DATA. All Doppler
echocardiographic examinations were performed and
analyzed in the same laboratory by the same team of
sonographers and cardiologists. The investigators
who did the acquisition and analysis of the Doppler
echocardiographic images were blinded to the results
of all blood analyses including those of Lp-PLA2.
Aortic valve morphology and function. The AV pheno-
type (i.e., bicuspid vs. tricuspid AV) was recorded. The
Doppler echocardiographic indexes of AS severity
included Vpeak, peak and mean transvalvular pressure
gradients (MG) obtained with the modiﬁed Bernoulli
equation, and the AV area index (AVAi) calculated by
the standard continuity equation and indexed to the
BSA. The degree of AV calciﬁcation was scored ac-
cording to the criteria proposed by Rosenhek et al. (8).
Left ventricular hemodynamic load and function. As
ameasure of global left ventricular hemodynamic load,
we calculated the valvuloarterial impedance: Zva ¼
(SBP þ DPmean)/SVi, where SBP is the systolic blood
pressure, DPmean is the mean transvalvular gradient,
and SVi is the stroke volume indexed to the BSA (9).
LVEFwasmeasuredwith the biplane Simpsonmethod.
STUDY ENDPOINTS. The primary endpoint for this
study was the progression rate of valve stenosis
TABLE 1 Baseline Characteristics of the Study Population According to Circulating Lp-PLA2 Activity
All Patients
(N ¼ 183)
Lp-PLA2 Activity <11.4
(n ¼ 96) (52%)
Lp-PLA2 Activity >11.4
(n ¼ 87) (48%) p Value
Clinical
Age, yrs 66.00  13.00 67.00  13.00 65.00  13.00 NS
Male 70 66 77 0.07
Height, cm 166.00  9.00 165.00  8.00 168.00  9.00 0.03
Weight, kg 79.00  14.00 77.00  15.00 80.00  14.00 NS
Body surface area, m2 1.87  0.20 1.84  0.20 1.90  0.19 0.05
Body mass index, kg/m2 28.30  4.10 28.10  4.30 28.40  4.00 NS
History of hypertension 74 77 70 NS
Systolic blood pressure, mm Hg 134.00  20.00 135.00  20.00 133.00  19.00 NS
Diastolic blood pressure, mm Hg 74.00  10.00 73.00  11.00 75.00  10.00 NS
History of dyslipidemia 67 75 57 0.02
History of diabetes 22 28 16 0.05
History of coronary artery disease 40 48 31 0.02
Medication
Beta-blockers 33 41 25 0.03
ACE inhibitors 32 32 31 NS
ARBs 30 35 23 0.07
Statin 67 76 57 0.007
Antidiabetes 22 28 15 0.03
Laboratory data
LDL cholesterol, mmol/l 2.35  0.82 2.07  0.63 2.65  0.91 <0.0001
HDL cholesterol, mmol/l 1.43  0.40 1.48  0.44 1.37  0.33 0.05
Triglycerides, mmol/l 1.44  0.77 1.26  0.57 1.63  0.10 0.001
Fasting glucose, mmol/l 5.70  1.40 5.80  1.60 5.20  1.30 NS
Creatinine, mmol/l 86.00  25.00 87.00  26.00 85.00  25.00 NS
Lp-PLA2 activity, nmol/min/ml 11.90  2.90 9.70  1.20 14.20  2.30 <0.0001
Lp-PLA2 mass, ng/ml 122.00  43.00 97.00  29.00 149.00  39.00 <0.0001
Doppler echocardiographic data
Bicuspid aortic valve 18 15 21 NS
Aortic valve calciﬁcation score 2.50  0.60 2.50  0.60 2.60  0.50 NS
Peak aortic jet velocity, m/s 2.80  0.60 2.80  0.60 2.80  0.60 NS
Peak transvalvular gradient, mm Hg 34.00  14.00 34.00  14.00 34.00  14.00 NS
Mean transvalvular gradient, mm Hg 19.00  9.00 19.00  9.00 19.00  9.00 NS
Aortic valve area, cm2 1.26  0.29 1.22  0.29 1.30  0.29 NS
Indexed aortic valve area, cm2/m2 0.68  0.16 0.67  0.17 0.69  0.15 NS
Valvuloarterial impedance, mm Hg/ml/m2 3.60  0.70 3.60  0.70 3.50  0.80 NS
LV ejection fraction, % 65.00  6.00 66.00  6.00 65.00  6.00 NS
Values are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; ARBs ¼ angiotensin receptor blockers; HDL high-density lipoprotein; LDL ¼ low-density lipoprotein; Lp-PLA2 ¼ lipoprotein-
associated phospholipase A2; LV ¼ left ventricular.
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28measured by Doppler echocardiography. To account
for different follow-up lengths, annualized changes
in Vpeak, MG, and AVAi were calculated by dividing
the difference between last follow-up and baseline
values by the time duration of follow-up. The sec-
ondary endpoint was the change in AS severity class
(i.e., transition from mild to moderate or severe AS)
during follow-up.
STATISTICAL ANALYSIS. Continuous data were
expressed as mean  SD and compared with the
Student t test according to Lp-PLA2 activity dichoto-
mized at the median value (i.e., 11.4 nmol/min/ml).
The continuous variables were tested for normality ofdistribution and homogeneity of variances with the
Shapiro-Wilk and Levene tests, respectively. Cate-
gorical data were expressed as percentages and
compared with the chi-square or Fisher exact test
where appropriate. Univariable linear regression an-
alyses were performed to identify the impact of
plasma Lp-PLA2 activity and mass on AS progression
rate (i.e., annualized progression rates of Vpeak, MG,
and AVAi) and the interaction between Lp-PLA2
activity or mass and baseline AS severity. To deter-
mine whether Lp-PLA2 activity is independently
associated with the stenosis progression rate, we built
a multivariable linear regression model that included
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29variables with a p value <0.10 on individual analysis
as well as traditional cardiovascular risk factors.
Variables entered in the model, other than Lp-PLA2
activity, were age, sex, hypertension, diabetes, LDL
cholesterol, statin therapy, creatinine level, bicuspid
AV phenotype, degree of AV calciﬁcation, baseline AS
severity (i.e., Vpeak, MG, or AVAi). The independent
correlates of Lp-PLA2 activity were assessed by
multivariable linear regression. Standardized regres-
sion coefﬁcients were presented as mean  SE (beta
coefﬁcient  SE). The Kaplan-Meier curve and log-
rank test of the time-to-event data were used to
assess the transition from mild to moderate or severe
AS according to median value of plasma Lp-PLA2 ac-
tivity. Multivariable Cox proportional hazard analysis
adjusted for age, sex, degree of AV calciﬁcation and
baseline AS severity, was performed to determine the
independent association between Lp-PLA2 activity
and the worsening of AS severity class. Multivariate
models were inspected for multicollinearity by
calculating the variance inﬂation factor. A p value
<0.05 was considered statistically signiﬁcant.
RESULTS
POPULATION CHARACTERISTICS. Table 1 shows the
baseline characteristics of the 183 patients included in
this study. The mean age was 66  13 years, 70% were
men, 74% had systemic arterial hypertension, 67%
had dyslipidemia, 22% had diabetes, and 40% had
coronary artery disease. Eighteen percent of patients
presented a bicuspid AV phenotype, 67% had mild
(Vpeak <3.0 m/s), 29% moderate (Vpeak 3.0 to 3.9 m/s),
and 4% severe (Vpeak >4.0 m/s) AS at baseline.
The baseline Lp-PLA2 activity was 11.9  2.9
nmol/min/ml, and the plasma Lp-PLA2 mass was 122
 43 ng/ml (Table 1). Lp-PLA2 activity correlated with
Lp-PLA2 mass (r ¼ 0.78, p < 0.001). Patients with
increased Lp-PLA2 activity (i.e., median value, >11.4
nmol/min/ml) had lower prevalence of dyslipidemia
(p ¼ 0.02), diabetes (p ¼ 0.05), and coronary artery
disease (p ¼ 0.02), and they were less often treated
with beta-blockers, statins, antidiabetes drugs
compared with patients with low Lp-PLA2 activity
(Table 1). They also had higher LDL cholesterol
(p < 0.0001) and triglycerides (p ¼ 0.001) and lower
HDL cholesterol (p ¼ 0.05) (Table 1). Regarding
Doppler echocardiographic data, patients with high
versus low plasma Lp-PLA2 activity had similar
baseline AS severity, Zva, and LVEF (Table 1).
IMPACT OF PLASMA LP-PLA2 ON AS PROGRESSION
RATE AND INTERACTION WITH BASELINE AS
SEVERITY. During the mean follow-up of 2.5  1.4
years, patients with increased Lp-PLA2 activity had anonsigniﬁcant trend for faster AS progression rate
(annualized Vpeak 0.17  0.23 m/s/year vs. 0.12  0.18
m/s/year, p ¼ 0.14) (Figure 1A). There was no signiﬁ-
cant association between increased plasma Lp-PLA2
mass (i.e., median value >119.3 ng/ml) and AS pro-
gression rate (annualized Vpeak 0.15  0.23 m/s/year
vs. 0.14  0.19 m/s/year, p ¼ 0.88).
There was a signiﬁcant interaction between Lp-
PLA2 activity and baseline AS severity on AS pro-
gression rate (i.e., all interaction p values <0.05 for
Vpeak, MG, and AVAi), suggesting that the impact of
circulating plasma Lp-PLA2 activity on AS progression
rate differed depending on patients’ baseline AS
severity. Interaction between circulating plasma Lp-
PLA2 mass and baseline AS severity on AS progres-
sion did not reach statistical signiﬁcance (i.e., all
interaction p values >0.20). We thus performed
separated analyses in the subset of patients with mild
AS and moderate or severe AS. In patients with mild
AS (i.e., Vpeak <3.0 m/s, n ¼ 123) (Online Table 1),
stenosis progression rate was 2-fold faster in the
subset of patients with increased Lp-PLA2 activity
(annualized progression of Vpeak 0.16  0.18 m/s/year
vs. 0.09  0.14 m/s/year, p ¼ 0.01) (Figure 1B). On the
other hand, there was no association between Lp-
PLA2 activity and stenosis progression rate in the
patients with moderate or severe AS (annualized
Vpeak 0.20  0.33 m/s/year vs. 0.19  0.23 m/s/year,
p ¼ 0.99) (Figure 1C). Similar results were obtained
with annualized progression of MG and AVAi (Online
Figure 1 and Online Table 1).
Lp-PLA2 activity or mass expressed in continuous
variables was not associated with AS progression in
the whole cohort (all p > 0.20) (Table 2). On uni-
variable analysis, Lp-PLA2 activity was signiﬁcantly
associated with faster AS progression rate (annual-
ized Vpeak p ¼ 0.02; annualized MG: p ¼ 0.05; annu-
alized AVAi: p ¼ 0.03) in patients with mild AS but not
patients with moderate or severe AS (all p > 0.20)
(Table 2). On multivariable analysis adjusted for age,
sex, hypertension, diabetes, LDL cholesterol, statin
therapy, creatinine level, bicuspid AV phenotype,
degree of AV calciﬁcation, and AS severity, Lp-PLA2
activity was independently associated with a faster
annualized progression rate of Vpeak (p ¼ 0.005), MG
(p ¼ 0.02), or AVAi (p ¼ 0.02) in the subset of patients
with mild AS (Table 2, multivariable models). The
variance inﬂation factor was <5, thus conﬁrming that
the level of multicollinearity in these multivariable
models is acceptable.
AS SEVERITY CLASS. During follow-up, 46 patients
with mild AS progressed from mild to moderate or
severe AS. Increased Lp-PLA2 activity was associated
with a higher incidence of progression to more severe
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FIGURE 1 Progression Rate of AS According to the
Median Value of Plasma Lp-PLA2 Activity
Comparison of annualized progression of Vpeak in the whole
cohort (N ¼ 183) (A), in patients with mild AS (B) (Vpeak
<3.0 m/s; n ¼ 123), and in patients with moderate/severe AS
(C) (Vpeak $3.0 m/s; n ¼ 60) according to the median value of
Lp-PLA2 activity (i.e., 11.4 nmol/min/ml). The numbers on top of
the bars are mean annualized Vpeak  SEM. Error bars represent
the SEM. AS ¼ aortic stenosis; Lp-PLA2 ¼ lipoprotein-associated
phospholipase A2; Vpeak ¼ peak aortic jet velocity.
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30AS severity class (p ¼ 0.005) (Figure 2). For each unit
of Lp-PLA2 activity (1 nmol/min/ml), patients had
19% increased risk of progressing to a more severe AS
class (hazard ratio: 1.19, 95% conﬁdence interval: 1.08
to 1.32, p ¼ 0.001) (Figure 2). After adjustment for age,
sex, degree of AV calciﬁcation, and baseline AS
severity, Lp-PLA2 activity remained signiﬁcantly
associated with a higher risk of progression to a more
severe class (hazard ratio: 1.16, 95% conﬁdence in-
terval: 1.02 to 1.31, p ¼ 0.02) (Figure 2).
CORRELATES OF PLASMA LP-PLA2 ACTIVITY. Lp-
PLA2 activity was associated with male sex (p ¼ 0.04),
larger BSA (p ¼ 0.006), higher LDL cholesterol and
triglycerides (both p < 0.001), as well as lower HDL
cholesterol (p ¼ 0.001) and fasting glucose (p ¼ 0.04)
(Table 3). There was a trend for an association be-
tween Lp-PLA2 activity level and younger age
(p ¼ 0.09). After adjustment for these variables,
higher LDL cholesterol (p < 0.001) as well as lower
HDL cholesterol (p ¼ 0.001) and lower fasting glucose
(p ¼ 0.02) remained independently associated with
higher circulating Lp-PLA2 activity (Table 3). There
was no signiﬁcant interaction (p > 0.20) between LDL
cholesterol and Lp-PLA2 activity with regard to AS
progression rate.
DISCUSSION
The main ﬁnding of this study is that increased
plasma Lp-PLA2 activity is associated with a faster
progression rate of AS in earlier stages of the disease.
Lp-PLA2 mass was not associated with AS progres-
sion. This ﬁnding could be explained by the fact that
there is an important interindividual variation in the
Lp-PLA2 activity for a given Lp-PLA2 mass, and a
previous study reported that Lp-PLA2 activity is, at
least in part, genetically determined (10). It is thus
possible that the enzyme activity, which takes into
account both the mass and the genotype, provides a
better marker of the impact of Lp-PLA2 on AS devel-
opment and progression.
LP-PLA2 AND AS. We recently reported that Lp-PLA2
is highly expressed in AS valves and promotes ectopic
valve mineralization (6). Lp-PLA2 uses oxidized
phospholipids to produce LPC (11–13). We showed
that Lp-PLA2 is transported in the AV by LDL particles
and also secreted locally by macrophages and that the
product of Lp-PLA2 activity, LPC, is present in AS
valves (6). Tissue Lp-PLA2 activity also correlated
with the mineral content of the AV. In vitro, we
documented that LPC is a strong promoter of AV
mineralization through both an osteogenic transition
of cells and apoptosis. In the present study, we found
TABLE 2 Impact of Lp-PLA2 Activity and Mass on AS Progression Rate
Whole Cohort
(N ¼ 183)
Mild AS Patients
(n ¼ 123)
Moderate/Severe AS Patients
(n ¼ 60)
Univariable Analysis Univariable Analysis Multivariable Analysis Univariable Analysis
Beta-Coefﬁcient  SE p Value Beta-Coefﬁcient  SE p Value Beta-Coefﬁcient  SE p Value Beta-Coefﬁcient  SE p Value
Annualized progression rate of peak
aortic jet velocity, m/s/yr
Lp-PLA2 activity, nmol/min/ml 0.08  0.54 0.27 0.21 ± 0.50 0.02 0.33 ± 0.63 0.005 0.05  1.34 0.72
Lp-PLA2 mass, ng/ml 0.03  0.04 0.71 0.11  0.03 0.25 NA 0.03  0.09 0.81
Annualized progression rate of mean
gradient, mm Hg/yr
Lp-PLA2 activity, nmol/min/ml 0.02  0.09 0.75 0.17 ± 0.07 0.05 0.27 ± 0.09 0.02 0.10  0.23 0.45
Lp-PLA2 mass, ng/ml 0.02  0.006 0.82 0.11  0.005 0.19 NA 0.10  0.01 0.44
Annualized progression rate of aortic
valve area index, cm2/m2/yr
Lp-PLA2 activity, nmol/min/ml 0.05  0.001 0.48 0.19 ± 0.002 0.03 0.30 ± 0.002 0.02 0.05  0.003 0.70
Lp-PLA2 mass, ng/ml 0.01  0.001 0.85 0.05  0.001 0.56 NA 0.06  0.001 0.66
Beta-coefﬁcient is the standardized regression coefﬁcient  SE. The multivariate model is adjusted for age, sex, hypertension, diabetes, low-density lipoprotein cholesterol, statin therapy, creatinine level,
bicuspid aortic valve phenotype, degree of aortic valve calciﬁcation, and aortic stenosis severity at baseline (i.e., peak aortic jet velocity, mean gradient, or aortic valve area index, respectively). Bold values
indicate statistical signiﬁcance.
AS ¼ aortic stenosis; Lp-PLA2 ¼ lipoprotein-associated phospholipase A2; NA ¼ not applicable.
Log Rank: p = 0.005
†HR = 1.19; 1.08-1.32; p = 0.001
‡HR = 1.16; 1.02-1.31; p = 0.02
LP-PLA2 Activity <11.4
LP-PLA2 Activity >11.4
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FIGURE 2 Comparison of the Time-to-Event Curve for the Change from Mild to
Moderate or Severe AS According to a Median Value of Plasma Lp-PLA2 Activity
The Kaplan-Meier curves for the change in AS severity class (i.e., change from mild to
moderate or severe AS deﬁned as Vpeak>3.0m/s). †Univariable hazard ratio (HR) for increase
in 1 nmol/min/ml. ‡Multivariate HR adjusted for age, sex, degree of aortic valve calciﬁcation,
and baseline AS severity for increase in 1 nmol/min/ml. Abbreviations as in Figure 1.
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31an independent association between Lp-PLA2 activity
and faster AS progression in patients with mild AS
but not in patients with more advanced AS. These
ﬁndings support the hypothesis that lipid-mediated
mineralizing processes may be predominantly in-
volved in earlier stages of disease, as suggested by
previous studies (14–20). In more advanced disease
stages, further mineralization of the AV may be, in
large part, determined by phosphocalcic factors
(21,22).
In the present work, we found that higher levels of
LDL cholesterol as well as lower levels of HDL choles-
terol were independently associated with higher ac-
tivity of circulating Lp-PLA2. These metabolic features
have previously been associated with enhanced pro-
duction, accumulation, and oxidation of lipids within
the AV (2,4,18,19), which may in turn increase the
production of substrate for Lp-PLA2 and thus the
production of the pro-mineralizing LPC. The oxidized
lipids-Lp-PLA2-LPC pathway may thus explain, at
least in part, the previously reported associations
between dyslipidemia, metabolic syndrome, diabetes,
and AV calciﬁcation (17,23–28). However, although Lp-
PLA2 activity was correlated with LDL cholesterol
levels, the results of the multivariable analyses per-
formed in this study suggest that the effect of Lp-PLA2
activity on AS progression is independent of LDL.
We previously reported that the proportion of
circulating small, dense LDLs was associated with
the accumulation of oxidized LDL within the AV
(2). Small dense LDLs are prone to oxidation and
carry oxidized phospholipids, which is the main sub-
strate for Lp-PLA2 (29–31). Moreover, oxidizedphospholipids are also transported and sequestered
in the blood by lipoprotein(a) (32,33) and it has
been shown in recent studies that plasma levels
of lipoprotein(a) and corresponding genotypes were
TABLE 3 Correlates of Plasma Lp-PLA2 Activity
Lp-PLA2 activity
Univariable Analysis Multivariable Analysis
Beta-Coefﬁcient  SE p Value Beta-Coefﬁcient  SE p Value
Age, yrs 0.13  0.02 0.09 0.01  0.01 0.87
Male 0.16  0.46 0.04 0.15  0.50 0.07
Body surface area, m2 0.20  1.07 0.006 0.10  1.17 0.19
Fasting glucose 0.16  0.15 0.04 0.15 ± 0.12 0.02
LDL cholesterol 0.46  0.23 <0.001 0.51 ± 0.22 <0.001
HDL cholesterol 0.25  0.53 0.001 0.24 ± 0.51 0.001
Triglycerides 0.28  0.27 <0.001 0.11  0.24 0.10
Beta-coefﬁcient is the standardized regression coefﬁcient  SE. Bold values indicate statistical signiﬁcance.
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; Lp-PLA2 ¼ lipoprotein-associated phospho-
lipase A2.
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32associated with AS (34–36). Hence, several mecha-
nisms, which are independent of the effect of statins,
may promote the entry of lipids within the AV.
CLINICAL IMPLICATIONS. Statins failed to slow the
progression of AS, even in early stages of the disease
(37–40). This may be explained by the fact that
several mechanisms, which are independent of the
effect of statins or circulating LDL cholesterol levels,
may promote the entry, retention, and oxidation of
lipids within the AV (2,4,28,41). Although statins are
very efﬁcient in lowering the total LDL levels, they do
not appreciably modify the proportion of small, dense
LDLs or the lipoprotein(a) levels (24,42,43).
Our results, combined with those of recent studies
lend support to the hypothesis that reducing Lp-PLA2
activity may reduce the lipid-mediated mineralization
of AVs and thereby contribute to slowing the stenosis
progression rate, particularly in patients with mild AS.
Lifestyle modiﬁcation aimed at increased physical
activity and dietary changes may help to reduce
visceral obesity and associated metabolic abnormal-
ities including Lp-PLA2 activation (44). Direct inhibi-
tion of Lp-PLA2 activity with pharmacological agents
such as darapladib may also be considered (36).
However, recent randomized, controlled trials failed
to demonstrate any signiﬁcant beneﬁt of darapladib in
patients with acute coronary syndrome or stable
ischemic heart disease (45,46). However, the cellular
structure and biology are different in the AV versus thevasculature, and the mechanisms determining disease
progression and clinical events also differ substan-
tially between AS and atherosclerosis. In AS, the
calciﬁcation of the AV is the predominant mechanism
responsible for disease progression and occurrence of
events, whereas in coronary artery disease, lipid
deposition/modiﬁcation and inﬂammation are the
main causative mechanisms. The results of the pre-
sent study as well as those of our previous experi-
mental study (6) suggest that increased Lp-PLA2
activity may enhance the production of LPC within the
valve and thereby induce mineralization of valvular
tissues. Further trials are needed to assess the efﬁcacy
and safety of Lp-PLA2 inhibitors in patients with aortic
sclerosis and/or mild AS.
STUDY LIMITATIONS. This study is subject to the
inherent limitation of a prospective observational
study. In particular, this design does not allow us to
establish a causal relationship between Lp-PLA2 and
pathogenesis of AS.
CONCLUSIONS
In this study, there was no signiﬁcant association
between plasma Lp-PLA2 activity or mass and ste-
nosis progression in the whole cohort. However,
increased Lp-PLA2 activity was a powerful indepen-
dent predictor of a faster AS progression rate in pa-
tients with mild AS. These ﬁndings suggest that
inhibiting Lp-PLA2 activity may be a valuable
approach to slow AS progression and provide an
impetus for the elaboration of a randomized trial to
assess the effect of such intervention in patients with
early stages of calciﬁc AV disease.
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